This company listing is no longer active
Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!
Kazia Therapeutics Yönetim
Yönetim kriter kontrolleri 0/4
We currently do not have sufficient information about the CEO.
Anahtar bilgiler
John Friend
İcra Kurulu Başkanı
AU$1.6m
Toplam tazminat
CEO maaş yüzdesi | 47.1% |
CEO görev süresi | less than a year |
CEO sahipliği | n/a |
Yönetim ortalama görev süresi | less than a year |
Yönetim Kurulu ortalama görev süresi | 1.3yrs |
Son yönetim güncellemeleri
Recent updates
We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn
Jun 24We're Not Worried About Kazia Therapeutics' (ASX:KZA) Cash Burn
Feb 24We Take A Look At Why Kazia Therapeutics Limited's (ASX:KZA) CEO Compensation Is Well Earned
Nov 03We Think Kazia Therapeutics (ASX:KZA) Can Easily Afford To Drive Business Growth
Sep 23We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
May 04When Will Kazia Therapeutics Limited (ASX:KZA) Turn A Profit?
Mar 27Could The Kazia Therapeutics Limited (ASX:KZA) Ownership Structure Tell Us Something Useful?
Feb 28What Can We Learn About Kazia Therapeutics' (ASX:KZA) CEO Compensation?
Feb 01We Think Kazia Therapeutics (ASX:KZA) Can Afford To Drive Business Growth
Jan 06Bullish: Analysts Just Made An Incredible Upgrade To Their Kazia Therapeutics Limited (ASX:KZA) Forecasts
Dec 11Kazia Therapeutics Limited (ASX:KZA): When Will It Breakeven?
Nov 26CEO Tazminat Analizi
Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
---|---|---|---|
Jun 30 2023 | AU$2m | AU$743k | -AU$20m |
Mar 31 2023 | n/a | n/a | -AU$23m |
Dec 31 2022 | n/a | n/a | -AU$25m |
Sep 30 2022 | n/a | n/a | -AU$25m |
Jun 30 2022 | AU$1m | AU$430k | -AU$25m |
Tazminat ve Piyasa: John's total compensation ($USD1.03M) is above average for companies of similar size in the Australian market ($USD295.83K).
Tazminat ve Kazançlar: John's compensation has increased whilst the company is unprofitable.
CEO
John Friend (53 yo)
less than a year
Görev süresi
AU$1,576,913
Tazminat
Dr. John E. Friend, II, M. D., serves as Chief Executive Officer at Kazia Therapeutics Limited since May 01, 2023 and since August 1, 2023 serves as Managing Director and Director and served as Chief Medic...
Liderlik Ekibi
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO, MD & Interim Chairman | less than a year | AU$1.58m | Veri yok | |
Chief Financial Officer | 1.8yrs | AU$1.05m | Veri yok | |
Company Secretary | less than a year | Veri yok | Veri yok |
0.8yrs
Ortalama Görev Süresi
Deneyimli Yönetim: KZA's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.
Yönetim Kurulu Üyeleri
İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
---|---|---|---|---|
CEO, MD & Interim Chairman | less than a year | AU$1.58m | Veri yok | |
Independent Non-Executive Director | 8.4yrs | AU$94.00k | 0.36% A$ 68.5k | |
Member of Scientific Advisory Board | 1.3yrs | Veri yok | Veri yok | |
Independent Non-Executive Director | 11yrs | AU$94.00k | 0.42% A$ 79.4k | |
Director | less than a year | AU$7.12k | Veri yok | |
Member of Scientific Advisory Board | 1.3yrs | Veri yok | Veri yok | |
Member of Scientific Advisory Board | 1.3yrs | Veri yok | Veri yok | |
Member of Scientific Advisory Board | 1.3yrs | Veri yok | Veri yok |
1.3yrs
Ortalama Görev Süresi
61yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: KZA's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.